Big news for Dynavax, a company that makes a hepatitis B vaccine! A big investor, Deep Track Capital, wants Dynavax to focus all its energy on making and selling this vaccine. They think Dynavax is spending too much money on other things.
- Deep Track wants Dynavax to focus on its Heplisav vaccine.
- Deep Track nominated new people to Dynavax's board to make changes.
- Deep Track thinks Heplisav can make over $1 billion by 2030.
| Item | Number |
|---|---|
| Dynavax's Stock Price Increase (Wednesday) | 1.24% |
| Dynavax's Stock Price Increase (Year-to-Date) | 1.47% |
| Dynavax's Stock Price Increase (Last 52 Weeks) | 6.6% |
| Deep Track's Stake in Dynavax | 13.5% |
| Deep Track's Assets | $4 billion |
| Dynavax's Cash on Hand (End of Last Year) | $714 million |
| Projected Heplisav Cash Generation (Through 2030) | Over $1 Billion |
